BUZZ-Hbm climbs on progress of AstraZeneca collaboration ** Shares of Hbm Holdings 2142.HK climb 2.3% to HK$13.2, on course for the biggest one-day pct gain since Nov 14
** Hbm said the scope of collaboration with AstraZeneca AZN.L was further advanced following an amendment to an earlier agreement, aiming to develop next-generation biotherapeutics including antibody-drug conjugates and T cell engagers
** The therapeutics developer for immuno-oncology and immunology diseases said the economic terms remain consistent with the financial framework established under the agreement
** YTD, stock up 590%, Hang Seng Biotech Index .HSBIO up 77.2%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments